Please ensure Javascript is enabled for purposes of website accessibility

Why Amgen Soared in April

By George Budwell - May 11, 2020 at 9:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amgen's stock ripped higher in April. Here's why.

What happened

Shares of the biotech heavyweight Amgen (AMGN -0.30%) gained an astounding 20.9% during the month of April, according to data from S&P Global Market Intelligence. Amgen's stock took flight in April for two underlying reasons. 

So what

First, Amgen's double-digit April rally initially got underway when the company announced a collaboration with Adaptive Biotechnologies (ADPT 0.79%) to develop an antibody against the COVID-19 respiratory illness. For reasons that aren't altogether clear, every biotech company associated with a COVID-19 treatment or vaccine has been racing higher of late. Amgen, for its part, proved to be no exception to this general trend.  

Close up view of the novel coronavirus.

Image source: Getty Images.

Second, Amgen, along with a host of other blue chip healthcare stocks, appeared to perk up last month in response to the harsh economic realities of this pandemic. While healthcare stocks aren't entirely immune to the economic impacts of COVID-19, many of these companies are still generating profits during this turbulent period. The same can't be said for most airlines, sit-down restaurants, or oil and gas companies right now. Amgen, in fact, recently reported fairly strong first-quarter sales across the bulk of its product portfolio. 

Now what

Is Amgen's stock still a screaming buy? Prior to this sizable upswing in April, Amgen was easily one of the most attractive value plays in the large-cap biotech space. At this point, however, Amgen's shares are arguably fairly valued at best. The company's shares, after all, are now trading at a hefty 5.3 times 2021 projected sales. That's not exactly bargain territory for a large-cap biotech stock. Therefore, investors may want to wait before buying shares.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
$246.25 (-0.30%) $0.73
Adaptive Biotechnologies Corporation Stock Quote
Adaptive Biotechnologies Corporation
$11.45 (0.79%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.